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number of patients pursuing this therapy at great financial cost and 
with high expectations. Regarding this technology, we would like to 
emphasise the following:
1. There is a complete absence of sound clinical evidence for the 
efficacy of stem cell therapy for ALS and neurodegenerative 
diseases in general. No randomised controlled studies or even 
open-label studies with long-term follow-up exist. Furthermore, a 
prospective case series in the Netherlands showed no benefit from 
treatment with olfactory ensheathing cells in patients with ALS.1
2. Long-term safety data on the use of stem cell therapy in neurological 
disorders are lacking.
3. Currently, the main utility for stem cell technology in neurological 
disorders is the ability to offer human in vitro models for 
understanding disease mechanisms and facilitating drug discovery. 
Although the potential for cell-based therapy exists, current claims 
of efficacy in ALS and other neurodegenerative disorders are 
premature and unsubstantiated.
We have strong scientific, ethical and economic objections to 
clinics offering stem cell therapy on a commercial basis, as well as 
medical practitioners recommending (or not advising against) this 
modality for neurological disorders. Patients with incurable diseases 
such as ALS are desperate and emotionally vulnerable to the claims 
of institutions allegedly being able to heal a number of diseases that 
modern medicine is unable to. Although we respect their autonomy 
and right to self-determination, patients are seldom equipped to 
assess the evidence for or against different treatment modalities, 
and are therefore reliant on medical professionals in decision-
making. Moreover, regulations guiding stem cell research and therapy 
are sorely lacking in South Africa.2 It is therefore the healthcare 
professional’s moral duty to present patients and their families with 
relevant information in an understandable manner. In the case of 
stem cell therapy, this involves a thorough discussion about the 
absence of scientific evidence and the likelihood that substantial 
sums will be paid by patients for no discernible benefit. Failing to do 
so, in our view, is unethical and not in the best interests of the patient.
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Hydatid cysts of the breast and parotid 
gland
To the Editor: We report 2 interesting cases of hydatid cysts in 
unusual sites: in the breast and the deep lobe of the parotid gland.
Hydatid cysts are an infectious disease caused by the larval stage 
of the cestode Echinococcus. Humans are mostly affected by E. 
granulosus as incidental intermediate hosts. The liver (70%) and lungs 
(25%) are most commonly affected, with the spleen, heart, kidneys, 
bone, nervous system and soft tissue less frequently affected.1 Even 
in endemic areas, hydatid disease of the head, neck and breast is 
extremely rare. The incidence of hydatid cyst in the breast has been 
reported as 0.27%.2 No parotid gland incidence figures are available.
A 24-year-old woman from Van Wyksvlei was referred to the 
surgical clinic with a lump in the superolateral quadrant of the left 
breast. Fine-needle aspiration was performed at a local clinic before 
referral to the surgical clinic; parasitic hooklets were observed, 
diagnosing an Echinococcus cyst. Chest X-ray (CXR) and abdominal 
sonar showed no other cysts. Pre-operative albendazole was 
administered and the cyst was removed by excision biopsy (Fig. 1). 
There were no postoperative complications.
In the second case, an HIV-negative 20-year-old man from Britstown 
was referred with a cystic mass in the right parotid area. The cyst, 
present for about 2 years, had fluctuated in size. It appeared superficial 
on examination. In the absence of a radiologist at the facility, informed 
consent was obtained for excision of the cyst with or without superficial 
parotidectomy. On excision, the cyst appeared to extend into the deep 
lobe of the parotid gland. Superficial parotidectomy and excision of 
the cyst was performed without injury to the facial nerve. Histology 
confirmed normal superficial parotid tissue and an Echinococcus cyst. 
CXR and abdominal sonar showed no other cysts. The patient was 
given albendazole and discharged; he returned once for follow-up.
Hydatid disease is a prevalent parasitic infection in sheep-rearing 
areas such as the Northern Cape. Although hydatid cysts in the head, 
neck and breast are extremely rare, Echinococcus infection should be 
considered as a differential diagnosis in patients from endemic areas.
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Fig.1. Hydatid cyst excised from the breast.
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